CD151 and non-small cell lung carcinoma: This is consistent with findings that CD151 knockdown can enhance the sensitivity of NSCLC cells to inhibitors like gefitinib, suggesting a potential role for CD151 in improving clinical outcomes in NSCLC patients.35